Welcome to our dedicated page for Currenc Group Ordinary Shares news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group Ordinary Shares stock.
CURE PHARMACEUTICAL HOLDING COR (symbol: CURR), now known as Avenir Wellness Solutions, Inc., is at the forefront of innovative drug delivery and development. The company is dedicated to enhancing drug efficacy, safety, and the overall patient experience through its proprietary drug dosage forms and delivery systems. Avenir boasts an industry-leading full-service CGMP manufacturing facility and is renowned for its advanced oral thin film, Curefilm™, the most sophisticated oral thin film available today.
With a strong presence in the pharmaceutical cannabis sector and partnerships in the U.S., Canada, Israel, and Germany, Avenir is committed to improving how medicines are delivered and experienced worldwide. The company has developed a broad range of products using cutting-edge delivery platforms and collaborates with leading pharmaceutical companies.
Recently, Avenir has experienced significant growth, as evidenced by its financial performance. In the first quarter of 2023, the company reported a 15.1% increase in net revenue year-over-year and a 35.6% sequential increase from Q4 2022, reaching $1.2 million. Gross margins improved by 102 basis points to 78.9%, with further increases expected.
The company's strategic initiatives, including cost reductions and operating leverage, are expected to help narrow the net operating loss from continuing operations, excluding non-cash charges. Avenir's advertising and marketing campaigns, especially for its new product, DNA Complex, have garnered positive attention from prominent media outlets.
On August 9, 2023, the company officially changed its ticker symbol to AVRW and its corporate name to Avenir Wellness Solutions, reflecting its renewed focus on wellness technologies and high-margin products. The rebranding aligns with Avenir's long-term growth strategy to increase revenue through product development, strategic partnerships, and geographic licensing deals.
For more information, visit the company's website at avenirwellness.com.
Avenir Wellness Solutions (OTCQB:CURR) announced the launch of an informational series focused on its unique dual revenue model, highlighting breakthrough consumer wellness products and intellectual property (IP) monetization. In collaboration with New to The Street, the company aims to enhance its visibility through televised content featuring its leadership. CEO Nancy Duitch emphasized the company's innovative delivery technologies and its 15 patents in the wellness sector. This initiative is expected to increase Avenir's market share in a multi-billion-dollar industry, showcasing its commitment to growth and the advancement of its proprietary wellness solutions.
Avenir Wellness Solutions, Inc. (formerly CURE Pharmaceutical Holding Corp.) announced its corporate name change on January 17, 2023, following the sale of certain intellectual property. This rebranding aims to reflect a renewed focus on developing innovative wellness technologies in the beauty sector. The company plans to enhance shareholder value through an incubator strategy, expanding its patent portfolio, and leveraging partnerships with social media influencers. Avenir targets high-margin markets, including the $587.3 billion supplements industry, emphasizing its proprietary delivery systems to improve product efficacy and consumer experience.
CURE Pharmaceutical Holding Corp. (CURR) shares positive developments following its asset sale in July 2022. The company focuses on innovative wellness and beauty products, planning to enhance its market presence through strategic partnerships and influencer marketing, including collaboration with Nicole Kidman. Notable achievements include a 32.1% year-over-year revenue increase in Q3 2022, reaching $1.8 million, with gross margins improving to 80%. With a strong patent portfolio and new products launching in the first half of 2023, CURE is poised for growth in a booming wellness market projected to exceed $450 billion.
CURE Pharmaceutical Holding Corp. (OTCQB:CURR) reported a 32.1% year-over-year revenue increase in Q3 2022, reaching $1.8 million, with expectations of further growth in Q4. Gross margins improved to 80.0%, reflecting effective marketing initiatives. The company reduced SG&A expenses by $0.1 million and narrowed operating losses despite increasing marketing investments. A $20 million asset sale earlier this year enhanced their cash position, supporting future growth in innovative wellness solutions and marketing campaigns.
CURE Pharmaceutical Holding Corp. (OTC: CURR) reported a 31.2% increase in gross revenue, reaching $1.6 million for Q2 2022. The company successfully sold $20 million in assets, bolstering its cash position and reducing debt. SG&A expenses decreased by $3.4 million, while operating loss narrowed by $1.0 million. New marketing programs are yielding positive early results, with sales from the Seratopical skincare line ramping up in Walmart stores. Key appointments to the board enhance governance and strategic direction. CURE aims to accelerate high-margin sales and shareholder value initiatives.
CURE Pharmaceutical has appointed Rob Davidson as Chairman of the Board and Robert J. Costantino to the board, enhancing leadership with extensive financial experience. Davidson, a former CEO, will focus on product development and non-dilutive transactions, while Costantino brings decades of experience from previous leadership roles in financial operations. These changes aim to bolster shareholder value and support ongoing initiatives for growth, especially for the subsidiary The Sera Labs. The company emphasizes continuity and commitment to investors.
On August 3, 2022, CURE Pharmaceutical Holding Corp. (OTC: CURR) hosted a shareholder call to discuss a recent $20 million non-dilutive sale of part of its product and intellectual property portfolio. The executive team outlined their strategy to innovate and monetize their technology while building The Sera Labs brands to enhance shareholder value. The call's replay will be available until August 3, 2023. CURE is known for its patented drug delivery platform, CUREform™, which aims to improve drug efficacy and patient experience.
CURE Pharmaceutical has appointed Gerald Bagg to its board of directors, enhancing its expertise in the consumer packaged goods (CPG) and advertising sectors. Bagg, a 45-year veteran in advertising, aims to leverage his experience to bolster the company's branding efforts and drive growth for its subsidiary, The Sera Labs, Inc., which focuses on wellness and beauty products. This move increases the board's membership to five, aligning with CURE's strategy to develop and acquire innovative brands.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announces a teleconference on August 3, 2022, to discuss a recent $20 million non-dilutive sale of part of its product and IP portfolio. The company retains exclusive rights to its Nutraceutical Nutri-Strip products and is pursuing international transactions to monetize its extensive patent portfolio, which includes areas like CBD and psychedelics. CURE's subsidiary, The Sera Labs, plans to relaunch its Seratopical Revolution line, recently supplied to over 1,200 Walmart stores, as part of its strategy to enhance shareholder value.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced the sale of part of its intellectual property for $20 million. This transaction allows CURE to reduce debt and invest in its wellness and beauty brands. The company retains its proprietary platform technology, which it plans to monetize further. A conference call is scheduled for August 3, 2022, to update shareholders. CURE develops patented drug delivery systems and operates an FDA-registered facility, partnering with various health and beauty sectors globally.
FAQ
What is the current stock price of Currenc Group Ordinary Shares (CURR)?
What is the market cap of Currenc Group Ordinary Shares (CURR)?
What does Cure Pharmaceutical Holding Corp. do?
What is Curefilm™?
What are the financial highlights for the first quarter of 2023?
What recent changes has Avenir made to its corporate structure?
What is Avenir's mission?
How has Avenir's marketing strategy impacted their business?
What markets does Avenir operate in?
Who are Avenir's notable partners?
What is the significance of the name change to Avenir Wellness Solutions?
Where can I find more information about Avenir's financial performance?
